Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp
SHP2, ERK Inhibitors Disclosed After Two Years, $300m In Funding
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
You may also be interested in...
Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.
The Swiss giant's acquisition of Ignyta to get hold of the latter's closely-watched NSCLC drug entrectinib will potentially trigger an intriguing fight for market share in the near future with Loxo Oncology and Bayer's larotrectinib.
Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.